Vietnam's securities commission approved the purchase of Livzon Pharmaceutical (HKG:1513, SHE:000513) subsidiary Lian SGP of Vietnam-listed Imexpharm (HOSE:IMP) through a public tender.
Livzon previously raised the maximum purchase price for the acquisition to 1.85 billion yuan from 1.59 billion yuan in December 2025, according to a filing by parent company Joincare Pharmaceutical (SHA:600380) with the Shanghai bourse.
The Joincare subsidiary initially offered to acquire a 64.81% stake in antibiotic and cardiovascular drug manufacturer Imexpharm in May.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments